Factor VII antibody

Catalog No. ABIN458154

Product Details anti-Factor VII Antibody

Target: Factor VII (F7) (Coagulation Factor VII (F7))

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This Factor VII antibody is un-conjugated

Application: Immunoelectrophoresis (IEP), Immunodiffusion (ID)

Specificity: The antiserum does not cross-react with any other human plasma proteins as tested in gel-diffusion techniques. Inter-species cross-reactivity is a normal feature of antibodies to plasma proteins, since homologous proteins of different species frequently share antigenic determinants. of this antiserum has not been tested in detail, however in double radial immunodiffusion a reaction with Rhesus monkey has been observed.

Characteristics: Precipitating polyclonal rabbit antiserum to human coagulation factor VII

Purification: Adsorption: Immunoaffinity adsorbed using insolubilized antigens as required, to eliminate antibodies reacting with other human serum proteins. The use of insolubilized adsorption antigens prevents the presence of excess adsorbent protein or immune complexes in the antiserum.

Immunogen: Plasma factor VII is ea vitamin K-dependent glycoprotein (MW 63,000) with an electrophoresis mobility in the beta region. It circulates in plasma in a semi-active form, even in the absence of tissue factor. Then procoagulant activity of FVII can be destroyed by heating to 56ºC. It is unstable below pH 3 and above pH 9. It survives he clotting process and its presence can be demonstrated in serum. After isolation its molecular weight was 44,700. Factor VII is a serine protease depending on a lipid cofactor and can be activated to FVIIa by factors IXa, Xa and XIIIa, thereby linking the intrinsic and extrinsic coagulation systems since FXII and FIX can be activated by kallikrein. The normal adult plasma FVII level is about 0.5 to 1.0 µ g/ml. In normal newborn infants the average level is about 50% of the adult concentration. A deficiency of FVII, congenital or acquired, results in a bleeding disorder. The congenital form is rare but the acquired form is commonly seen in association with a deficiency of FII, FIX and FX in liver disease and in patients taking coumarin-type anticoagulant drugs. Both procoagulant activity and FVII-related antigen are depressed. In haemorrhagic disease of the newborn, procoagulant activity is reduced but not the level of the FVII antigen. A similar discrepancy may be seen in congenital deficiencies but in other types FVII antigen will be severely reduced as a result of genetic suppression of synthesis capacity. If still present, the FVII molecules appear to be biologically defective. Heterozygote carriers can now be detected. FVII procoagulant activity and related antigen levels have been shown to correlate directly with the plasma triglyceride concentration. This makes FVII a risk factor for myocardial infarction, immediately following an acute myocardial infarction patients have increased plasma FVII procoagulant activity. FVII is purified from plasma and Freund’s complete adjuvant is used in the first step of the immunization procedure.

Isotype: IgG

Application Details

Application Notes: In precipitating techniques as electroimmunodiffusion, immunoelectrophoresis, single and double radial immuno-diffusion (Mancini, Ouchterlony), bidimensional electrophoresis and neutralization assay. The presence of non-precipitating antibodies has not been assayed. If used in more sensitive test procedures or as catching or detection antibody in solid phase immunoassays specificity controls should always be include. Plasma samples and all assay components must contain EDTA to stabilize the proteins.

Restrictions: For Research Use only

Handling

Format: Lyophilized

Concentration: Total protein and IgG concentrations in the antiserum are comparable to those of pooled normal rabbit serum. No foreign proteins added. Antibody titre: The amount of Factor VII precipitated by 1 ml antiserum is approximately 100 U. One Unit of Factor VII

Buffer: Delipidated, heat inactivated, lyophilized, stable whole serum.

Preservative: Sodium azide

Precaution of Use: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C/-20 °C

Storage Comment: The lyophilized antiserum is shipped at ambient temperature and may be stored at +4°C, prolonged stora ge at or below -20°C. Reconstitute the lyophilized antiserum by add ing 1 ml sterile distilled water. Dilutions may be prepared by adding phosphate buffered saline (PBS, pH 7.2). Repeated thawing and freezing should be avoided. If a slight precipitation occurs upon storage, this should be removed by centrifugation. It will not affect the performance of the antiserum. Diluted antiserum should be stored at +4°C, not ref rozen, and preferably used the same day.

Target Details for Factor VII

Target: Factor VII (F7) (Coagulation Factor VII (F7))

Alternative Name: Coagulation Factor VII (F7 Products)

Synonyms: F7 antibody, wu:fb59f04 antibody, zgc:109870 antibody, SPCA antibody, AI114908 antibody, ATIII antibody, At-3 antibody, At3 antibody, LOC100223776 antibody, AI132620 antibody, Cf7 antibody, FVII antibody, mfVII antibody, f7 antibody, coagulation factor VII antibody, serine (or cysteine) peptidase inhibitor, clade C (antithrombin), member 1 antibody, coagulation factor 7 (serum prothrombin conversion accelerator) S homeolog antibody, F7 antibody, f7 antibody, Serpinc1 antibody, CpipJ_CPIJ009142 antibody, CpipJ_CPIJ010295 antibody, CpipJ_CPIJ020127 antibody, fa7 antibody, f7.S antibody

Background: The defined antibody reactivity is restricted to Factor VII. To demonstrate the presence of FVII in normal plasma or serum by gel-immunodiffusion or immunoelectrophoresis a concentrate must be prepared, because the normal concentration is below the detection limits of these techniques. The precipitation obtained with the concentrate shows a reaction of identity with that obtained with the purified factor. FVII shows micro-heterogeneity. The antiserum also reacts with FVII molecular variants and with abnormal, molecules (PIVKA VII)

Pathways: Response to Growth Hormone Stimulus, Platelet-derived growth Factor Receptor Signaling